Drug Profile
Research programme: small molecule gene expression modulators - Gilead/ PTC Therapeutics
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator PTC Therapeutics
- Developer Gilead Sciences; PTC Therapeutics
- Class Small molecules
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Low HDL cholesterol
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Low-HDL-cholesterol in USA (PO)
- 15 Mar 2010 Preclinical development is ongoing
- 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences